Bioventus BVS U.S. Segment — Adjusted selling expense

Similar metrics at other companies

HLMNCanada — Adjusted selling expense

$3.66M+14.3%

HLMNHardware and Protective Solutions — Adjusted selling expense

$30.3M+4.8%

HLMNRobotics and Digital Solutions — Adjusted selling expense

$19.39M+17.3%

PRMBReportable Segment — Selling expense, adjusted

$119.4M+1.9%

RMNIReportable Segment — Selling And Marketing Expense, Adjusted

$37.79M+13.4%

PCTYReportable Segment — Selling and Marketing Expense, Adjusted

$97.35M+5.0%

FAQ

What is Bioventus's U.S. segment — adjusted selling expense?

Bioventus (BVS) reported U.S. segment — adjusted selling expense of $39.05M in Q2 2026.

How has Bioventus's U.S. segment — adjusted selling expense changed year-over-year?

Bioventus's U.S. segment — adjusted selling expense increased by 4.5% year-over-year, from $37.35M to $39.05M.

What is the long-term trend for Bioventus's U.S. segment — adjusted selling expense?

Over 3 years (2022 to 2025), Bioventus's U.S. segment — adjusted selling expense has grown at a 1.0% compound annual growth rate (CAGR), from $147.77M to $152.08M.

What does U.S. segment — adjusted selling expense mean?

This metric measures the adjusted costs incurred by the sales force to promote and distribute products within the U.S. market. It reflects the investment required to maintain customer relationships and drive product adoption among orthopedic physicians and surgical centers.